MTOR and non-small cell lung carcinoma: Inhibiting ULK1 has shown promise in sensitizing CSCs to chemotherapy, as evidenced by the ULK1 inhibitor SBI-0206965, which, in combination with mTOR inhibitor, increases cisplatin sensitivity in non-small cell lung cancer [239].